GPs, nurses able to diagnose, treat ADHD from next year
Under the current system, GPs and nurses can only prescribe ADHD stimulant medicines on a written recommendation from a paediatrician or psychiatrist or after the patient has already been previously diagnosed with ADHD.
Pharmac's acting director of advice and assessment Catherine Epps said that the new rules decided by Pharmac and Medsafe will mean that, over time, more GPs and nurses will be able to diagnose people with ADHD and start treatment.
"The decision, which is based on feedback from psychiatrists, paediatricians, GPs, nurse practitioners and patients, is one of many changes we are making to increase access to ADHD medicines," said Epps.
For children and adolescents, the changes will enable nurse practitioners working within child health or mental health services to diagnose and initiate treatment for ADHD.
ADVERTISEMENT
Medsafe group manager Chris James said that New Zealand has a workforce of highly experienced GPs and nurse practitioners, with many already working closely with specialists to treat patients with ADHD.
"Implementing this change will mean they can do this work more quickly and efficiently without needing to wait for approval from a specialist," James said.
Minister for Mental Health Matt Doocey applauded the decision and said it was a step forward for patient support and system efficiency.
The morning's headlines in 90 seconds including Iran's retaliation, Auckland Council's catering cost, and the new way to look deep into space. (Source: 1News)
"This is a common-sense change that will make a meaningful difference in many lives of New Zealanders," Doocey said.
"I have heard stories of many people with ADHD who have been unable to get a diagnosis and treatment in a timely manner because of long wait items and costs associated with seeing a specialist."
Earlier this year, Medsafe and Pharmac received feedback from more than 940 people and organisations on the proposed change.
ADVERTISEMENT
The Ministry of Health said that most of the feedback was supportive, and people believed the decision would improve access to diagnosis and treatment.
However, some people were concerned about supply issues affecting the availability of methylphenidate. To address this, health agencies have delayed the implementation date from July 2025 to February 2026.
This will also allow GPs and nurse practitioners more time to develop further clinical expertise in ADHD.
Doocey said that the Ministry of Health is working with sector representatives to develop a clinical principles framework for the assessment and treatment of ADHD which will ensure quality and consistency for supporting patients.
"We have heard your feedback loud and clear, and we know the positive impact this decision will have on many people's ability to access what is often life-changing medicines."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Spinoff
2 hours ago
- The Spinoff
It's time to shut the alcohol industry out of health policy in Aotearoa
Alcohol is our most harmful drug, yet industry groups have inside access during the development of alcohol harm reduction strategy, where they can put pressure on officials to water down policy advice. It has to stop, argues Steve Randerson. Most New Zealanders would be shocked to learn the alcohol industry is regularly invited to help shape our national health policies on alcohol. But that's exactly what's happening. Recent information uncovered by RNZ through the Official Information Act shows senior health officials in the Public Health Agency are 'expected' to work directly with alcohol industry representatives. Who set this expectation or what the expectations entail is unclear, but the information reveals the agency's diligent response. Regular interactions occurred between four separate industry associations representing spirits, wine, beer and hospitality and the Public Health Agency, part of the Ministry of Health. A group manager with responsibilities for alcohol harm reduction, Ross Bell, emerged as the main conduit for contact. The interactions included regular meetings, ongoing email contact and consultation on alcohol harm reduction plans. The alcohol industry had been involved in the development of an action plan for foetal alcohol spectrum disorder. All four industry groups were invited to give input to a new guiding framework for spending the $16 million alcohol levy, a public fund meant to reduce harm; in contrast, to our knowledge, there was no opportunity for most of Aotearoa's major public health organisations that work on alcohol to contribute to the framework. One industry representative questioned a government refresh of New Zealand's outdated guidance on lower-risk drinking levels, which some other countries now set considerably lower to reflect current evidence of the health risks of alcohol. The partially completed project was subsequently put on hold. While the pause was described as an internal ministry decision, current systems leave ministry staff exposed to potential industry pressure and there is a concerning lack of transparency around possible industry influence. For instance, alcohol industry feedback on the alcohol levy framework was redacted from the OIA documents supplied to RNZ. There's a reason this matters. Alcohol is our most harmful drug. It causes cancer and foetal alcohol spectrum disorder, and costs our country more than $9 billion a year in health and social harm. The damage is sustained by our lack of effective safeguards around the supply and promotion of alcohol, such as online marketing and the higher numbers of outlets in communities at greater risk of harm. Communities around the country have long fought to have more say on where and how alcohol is sold, while well-funded alcohol industry groups have doggedly opposed such changes in our courts, media and parliament. In this context the inside access alcohol industry representatives are enjoying during the development of alcohol harm reduction strategy is disheartening. Industry involvement in public health policy isn't just bad practice. It's a major conflict of interest. This is why Health Coalition Aotearoa . Almost half the alcohol sold in Aotearoa is consumed in heavy drinking sessions, while lighter alcohol consumption also increases the risk of cancer and other diseases. Any steps that broadly reduce these harms will impact alcohol industry profits, creating an inescapable incentive to undermine or block effective change. A senior health official put it bluntly: 'In my experience… these alcohol interests have zero interest in reducing harm (or sales of booze) and a huge purse to fund their lawyers.' Despite this, the government continues to expect the alcohol industry to have a seat at the table, where they can put pressure on officials to water down policy advice to ministers well before the public has a say. In contrast, New Zealand is required to protect our tobacco control public health policies from the commercial interests of the tobacco industry – since 2005 we have been party to the World Health Organization's Framework Convention on Tobacco Control. This agreement recognises the 'irreconcilable conflict' between tobacco industry profits and public health. The same logic applies to alcohol – yet no such protections exist. The Ministry of Health and Customs have continued to interact with tobacco industry representatives for tobacco regulation purposes, but one improvement of Aotearoa signing the framework convention is they now both maintain a public register of these interactions, which should only occur where strictly necessary. Other parts of the government may not have been so scrupulous, however. NZ First politicians have been reported to be closely affiliated with industry executives, and several coalition government ministers have appeared to use similar arguments as tobacco industry representatives to defend their repeal of the tobacco endgame measures in the Smokefree Environments and Regulated Products Act 1990, suggesting a common script. While the New Zealand government is yet to fully implement its responsibilities under the framework convention, it is a strong step in the right direction, and Labour health spokesperson Ayesha Verrall has proposed legislation to promote stronger compliance. We urgently need a similarly stringent approach for alcohol and await new rules for engagement with the alcohol lobby being considered by the Ministry of Health. The World Health Organization's Global Alcohol Action Plan 2022-2030 is clear: governments should protect public policy to reduce alcohol harms from commercial and other vested interests that undermine health. Most New Zealanders agree – a recent poll found 71% believe the alcohol industry should have no role in alcohol policy development. This strong public support should give politicians the courage to draw clear boundaries around industry involvement in policy intended to reduce alcohol harm.
Scoop
3 hours ago
- Scoop
Pharmac Continues To Engage With Consumers
Associate Minister of Health Associate Education Minister David Seymour welcomes the establishment of Pharmac's new consumer working group to help Pharmac help reset how it works with health consumers. "For many New Zealanders, funding for pharmaceuticals is life or death, or the difference between a life of pain and suffering or living freely,' Mr Seymour says. 'My expectation is that Pharmac should have good processes to ensure that people with an illness, their carers and family, can provide input to decision-making processes. This is part of the ACT-National Coalition Agreement. 'Pharmac hosted a Consumer Engagement Workshop in March. Patients and advocates voiced their hopes at resetting the patient – Pharmac relationship. Pharmac published a report on the findings from the workshop. 'The report recommended that the Board invite workshop participants, in association with the wider consumer-patient representative community, to select a working group. The group would work with Pharmac's Board and management to reset the relationship between Pharmac and the consumer/representative community. 'The patient advocacy community selected Dr Malcolm Mulholland to lead the consumer working group. He has worked with consumers to select the other members of the working group. These members represent patients with a wide range of health conditions. They are named at the end of this release.' 'We've waited a long time for this opportunity. The work that Pharmac does is vitally important for the health of patients and their families, and this is why getting Pharmac to work as well as it can, will be the focus of the working group,' Dr Mulholland says. 'The consumer working group met for the first time yesterday to confirm the approach for the reset programme and agree the first set of actions. I look forward to hearing about their progress,' Mr Seymour says. 'I'm pleased to see the Board take the opportunity to continue to prioritise expanding opportunities and access for patients and their families by expanding access to more medicines for more groups. 'The working group reflects our commitment to a more adaptable and patient-centred approach. It follows my letters of expectations, the consumer engagement workshop, last year's Medicines Summit, and the acceptance of Patient Voice Aotearoa's White Paper as actions to achieve this. 'The Government is doing its part. Last year we allocated Pharmac its largest ever budget of $6.294 billion over four years, and a $604 million uplift to give Pharmac the financial support it needs to carry out its functions - negotiating the best deals for medicine for New Zealanders.' The consumer working group members are: Dr Malcolm Mulholland MNZM – Patient Voice Aotearoa Libby Burgess MNZM – Breast Cancer Aotearoa Coalition Tim Edmonds – Leukaemia and Blood Cancer NZ Chris Higgins – Rare Disorders NZ Francesca Holloway – Arthritis NZ Trent Lash – Heartbeats Charitable Trust Gerard Rushton – The Meningitis Foundation Rachel Smalley MNZM – The Medicine Gap Tracy Tierney – Epilepsy NZ Deon York – Haemophilia NZ
RNZ News
4 hours ago
- RNZ News
New working group looks to demystify Pharmac fund
New Zealand has over 100 medicines on the Options for Investment (OFI) List, which is priority medicines that are waiting to be publicly funded. Photo: 123rf Drug buying agency Pharmac is bringing patients and consumers to the table. It has announced a new Consumer and Patient Working Group after years of reviews calling for major change . The group, made up of the consumer and patient community, will help steer a 12-month reset, aimed at making Pharmac more open and responsive. It will decide what Pharmac focuses on for the reset programme, taking a hands-on role in the delivery of the work to ensure it reflects consumers' needs, values, and perspectives. Patient advocate, Dr Malcolm Mulholland, has been appointed Chair of the working group. He told Morning Report he hopes the group will provide clarity on how Pharmac chooses what drugs it funds. "People just do not know how Pharmac arrives at the decisions they do and why it takes so long. I think that's probably the major bugbear that patients experience, and that's one area that we are very keen to get involve with and try and improve it." Medicine NZ found on average, applications for funding have been with Pharmac for six years. New Zealand has over 100 medicines on the Options for Investment (OFI) List, which is priority medicines that are waiting to be publicly funded. The cost of clearing this list is estimated to be $1 billion. According to Medicine NZ, 1.4 million people would benefit from the medicines. Dr Mulholland, who has been apart of petitions to fund medicines taken to Parliament, criticised the need for patients to publicly put pressure on politicians to fund drugs. "It is not a healthy process, and it's not how overseas jurisdictions like Pharmac operate, it's actually very unusual," he said. "That shows us that the Pharmac process is sick, so to speak, and we need to improve it and get it well." Dr Mulholland said we need to improve the way Pharmac approves a medicine's funding in a much shorter time. He added government needs to fund Pharmac properly. Dr Malcolm Mulholland. Photo: RNZ / Jimmy Ellingham On Monday, Associate Health Minister David Seymour told Pharmac to modernise or it would fall behind . In a letter of expectations, Seymour said to the agency to "innovate and optimise" to increase access to medicines and continue the "positive culture shift" that's been underway, such as exploring ways to "utilise AI". His expectations also included to be more proactive in engaging with stakeholders and continue to involve patients early in the process. The Consumer and Patient Working Group members are:
